Liraglutide
FDA ApprovedGLP-1 receptor agonist
Liraglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that has been studied extensively in metabolic research. It has been investigated for its effects on glucose-dependent insulin secretion, glucagon suppression, and appetite regulation through GLP-1 receptor activation. Published research has examined its pharmacokinetics and metabolic effects. RaysunPeptide supplies Liraglutide for qualified research and laboratory applications.
Mechanism of Action
Binds and activates GLP-1 receptors, increasing glucose-dependent insulin secretion, reducing glucagon secretion, slowing gastric emptying and increasing satiety.
Key Benefits
Molecular Data
Research Indications
Diabetes
Improves glycemic control through glucose-dependent insulin secretion and suppression of glucagon.
Weight Loss
Reduces appetite and energy intake and produces clinically meaningful weight loss when combined with lifestyle intervention.
Metabolic
GLP-1 receptor activation increases satiety and reduces food intake.
Cardiometabolic
Weight reduction and metabolic improvements can improve several cardiovascular risk factors.
What to Expect
Side Effects & Safety
Common (Generally Mild)
- •Nausea
- •Diarrhea
- •Constipation
- •Vomiting
- •Abdominal discomfort
Stop Signs (Seek Medical Attention)
- ⚠Severe persistent abdominal pain
- ⚠Persistent vomiting or dehydration
- ⚠Severe allergic reaction
- ⚠Symptoms of severe hypoglycemia when used with glucose-lowering agents
Contraindications
- ✕Personal or family history of medullary thyroid carcinoma
- ✕Multiple Endocrine Neoplasia syndrome type 2
- ✕Pregnancy
- ✕Product-specific contraindications
FAQs
Is liraglutide a GLP-1 peptide?
Yes. Liraglutide is a modified 31-amino-acid GLP-1 receptor agonist with a fatty-acid side chain that extends its duration of action.
How long does liraglutide remain active?
Its pharmacokinetic half-life is approximately 13 hours, supporting once-daily administration.
